Low Bioavailability and High Immunogenicity of a New Brand of E. colil-Asparaginase with Active Host Contaminating Proteins

The drug l-asparaginase is a cornerstone in the treatment of acute lymphoblastic leukemia (ALL). The native E. colil-asparaginase used in Brazil until recently has been manufactured by Medac/Kyowa. Then a decision was taken by the Ministry of Health in 2017 to supply the National Health System with...

Descripción completa

Detalles Bibliográficos
Autores principales: Zenatti, Priscila Pini, Migita, Natacha Azussa, Cury, Nathália Moreno, Mendes-Silva, Rosângela Aparecida, Gozzo, Fabio Cesar, de Campos-Lima, Pedro Otavio, Yunes, José Andrés, Brandalise, Silvia Regina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5952248/
https://www.ncbi.nlm.nih.gov/pubmed/29550241
http://dx.doi.org/10.1016/j.ebiom.2018.03.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5952248/
https://www.ncbi.nlm.nih.gov/pubmed/29550241
http://dx.doi.org/10.1016/j.ebiom.2018.03.005

Ejemplares similares